

READY ON DAY 1

Building the world's first comprehensive portfolio of antiviral drugs.

1,900,000 lives lost worldwide before vaccines were available

15 percent increase in US mortality

23,000,000 US jobs lost

14,000,000,000,000 dollars in US economic damage

3.5 percent decrease in global GDP

Imagine if we had been ready

7,054,000 deaths worldwide

20 years of US educational progress erased

1,190,000 US deaths—70% more than *all combat deaths since 1775*

65,000,000 long COVID cases worldwide

27 percent of global population remains unvaccinated

Pandemics are not rare events

The number of zoonotic spillover events and reported deaths **increased at an exponential rate** from 1963 to 2019.¹

Annually, there are approximately²:

- 100 significant outbreaks (triggering WHO Disease Outbreak News reports)
- 5 new emerging infectious diseases

~25% probability of a pandemic \geq COVID-19 during 10-year period:

- Metabiota³ **22%-28%**
- Airfinity⁴ **27.5%**

Source:


1. BMJ Global Health, Nov 2023 2. WHO 3. Rebranded Gingko Bioworks 2022 4. London-based disease forecasting company.



Viruses have an Achilles' heel

- Viruses cluster into families
- Viruses within each family share common features that can be targeted by antiviral drugs

No one knows which specific viruses come next, but we do know the *families* from which they will likely emerge



GOAL: 2 drugs per high-risk family

broad-spectrum:

effective against multiple viruses in a given family

small molecule drugs:

organic compounds with low molecular weight (think aspirin, not biologics)

- Work against an entire virus family
 - Protect against future threats
 - No need for genetic sequence
- Can be shipped immediately to the point of outbreak
 - Reduce disease, hospitalization and death
 - Slow viral spread

16 drugs total



“Why isn’t anyone else doing this?”

Discovery gap

Academics focus on drug discovery, not drug development.

Pharma model

Businesses develop drugs to target specific indications for existing markets.

Disease X problem

There is no business model to fight diseases that don’t yet exist.

CHALLENGE: Incentivize antiviral R&D to prepare for Disease X

READDI is the solution


A mission-driven biotechnology company acting in the public interest, READDI accelerates broad-spectrum small molecule antiviral discovery and development.

Committed to equitable global access

Addressing market failure to disrupt the panic-neglect cycle of pandemic response



We are aggregating a portfolio of broad-spectrum drugs — from a coalition of innovators at different stages of development — to target all high-risk virus families.



READDI's Global Network: 63 collaborators and growing



Leadership

Founded by world-renowned virologists



Ralph S. Baric
Co-founder and
Scientific Adviser



Mark Heise
Co-founder and
Scientific Adviser



Nathaniel Moorman
Co-founder and
Scientific Adviser



James Rosen
CEO and Director



Fletcher Fairey
Executive VP,
Business



Logan Ward
Director of
Communications

Select Board Members



John Bamforth
30 years at Eli Lilly



Richard Burr
Former U.S.
Senator



Laurent Fraise
R&D Dir, Drugs for
Neglected Diseases Init



Lydia Ogden
Global Public Health
R&D Policy and
External Engagement
Leader, J&J



Barbara Stephenson
UNC Chief Global
Officer and former
U.S. Ambassador



Brad Wilken
Bill & Melinda
Gates Foundation




READDI leads the world in antiviral therapeutics R&D

- Core implementation partner in the 100 Days Mission, the global pandemic preparedness effort launched by the G7
- Lead contributor to *100 Days Mission Therapeutics Roadmap*
- Co-leading Therapeutics Development Coalition alongside the WHO, Unitaid, DNDi and others

“The highest priority is to gather resources to support READDI’s work. Drugs are the gating item.”

— Jeremy Farrar, WHO Chief Scientist




Preparing for the next threat




High-risk virus families


- Encompass all viruses that cause WHO priority diseases
- Likely origin of future Disease X
- No antivirals or vaccines exist to stop Disease X



Arenavirus




Bunyavirus




Coronavirus




Filovirus




Flavivirus



Orthomyxovirus



Paramyxovirus








Togavirus



READDI Prospective Pipeline

- 30 active programs and growing



	Discovery	Hit	Lead	Candidate	Phase 1
Orthomyxovirus (1)	Progressing				
Paramyxovirus (1)	Progressing				
Filovirus (3)	Progressing				
Flavivirus (5)	Progressing				
Coronavirus (10)	Progressing				
Togavirus (10)	Progressing				



World-class drug development and innovative financing to prepare humanity for Disease X.



Funders



THE UNIVERSITY
of NORTH CAROLINA
at CHAPEL HILL



BATTELLE



Help us prepare
for the next
pandemic.



READI

Rapidly Emerging Antiviral Drug Development Initiative